All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

EUFOREA consensus on biologics for CRSwNP with or without asthma

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000049" target="_blank" >RIV/00064190:_____/19:N0000049 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/19:10409742

  • Result on the web

    <a href="http://dx.doi.org/10.1111/all.13875" target="_blank" >http://dx.doi.org/10.1111/all.13875</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1111/all.13875" target="_blank" >10.1111/all.13875</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    EUFOREA consensus on biologics for CRSwNP with or without asthma

  • Original language description

    Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4R alpha, anti-IL5, and anti-IL5R alpha have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30225 - Allergy

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2019

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    ALLERGY

  • ISSN

    0105-4538

  • e-ISSN

    1398-9995

  • Volume of the periodical

    74

  • Issue of the periodical within the volume

    12

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    8

  • Pages from-to

    2312-2319

  • UT code for WoS article

    000476166100001

  • EID of the result in the Scopus database

    2-s2.0-85069662686